SC
LJPC

Steven Cohen’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Steven Cohen’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,056,663
Closed -$9.96M – 1361
2018
Q4 		$9.96M Buy
1,056,663
+12,763
+1% +$192K 0.05% 413
2018
Q3 		$21M Buy
+1,043,900
New +$27.3M 0.09% 288

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Steven Cohen's LJPC Position: Q1 2019 in Review

Steven Cohen sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2019, closing a stake of 1,056,663 shares — an estimated $9.96M sold.

Steven Cohen first reported a position in LJPC in Q3 2018 and held it in 2 quarters. The position peaked at $21M in Q3 2018. 80 funds tracked by Wall St. Rank hold LJPC as of Q1 2019.

  • Steven Cohen reported no remaining La Jolla Pharmaceutical Company position as of Q1 2019 after selling out during the quarter.
  • Steven Cohen sold 1,056,663 La Jolla Pharmaceutical Company shares in Q1 2019, an estimated $9.96M.
  • Steven Cohen first reported a position in La Jolla Pharmaceutical Company in Q3 2018 and held it in 2 quarters.
  • Steven Cohen's La Jolla Pharmaceutical Company position peaked at $21M in Q3 2018.
  • 80 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2019.

Based on Point72 Asset Management's 13F filing for Q1 2019, filed 15 May 2019.